Clinical Trial Update: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) [Phase 3]

View source ↗

Summary

Phase 3 study of ataluren in nonsense mutation Duchenne muscular dystrophy has completed. The document provides a trial update but does not include trial result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Translarna (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: COMPLETED